



October 3, 2006

Celsion Corporation Successful in Having American Medical Systems, Inc. Patent Infringement Suit Dismissed in Minnesota

American Medical Systems, Inc. Files New Patent Lawsuit in Delaware

Columbia, MD - October 3, 2006: CELSION CORPORATION (AMEX: CLN) today announced that on September 27, 2006, the U.S. District Court for the District of Minnesota dismissed the patent infringement lawsuit filed by American Medical Systems, Inc. (AMS) against Celsion Corporation (AMEX:CLN) for lack of personal jurisdiction. On September 28, 2006, AMS filed a new suit against Celsion in the U.S. District Court for the District of Delaware, where both companies are incorporated, alleging that Celsion's Prolieve Thermodilation® System infringes the patents previously asserted in the Minnesota suit.

Dr. Lawrence Olanoff, Celsion's President and Chief Executive Officer, commented, "As we previously stated, Celsion intends to vigorously defend itself against AMS' claims, and this win in the Minnesota court is evidence of our efforts in this regard."

ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of heat activated treatment systems for cancer.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.